SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
Date
BIOTECH HOLDINGS LTD.

~~(Exact~~P.O. ~~name~~Box of48134 RPO ~~Registrant~~Queensborough New asWestminster, ~~specified~~BC V3M ~~in its charter)~~ 0A7

PONews ~~Box 48134, RPO Queensborough, New Westminster, British Columbia, Canada, V3M 0A7~~ Release

~~(Address~~For Immediate ~~of principal executive offices)~~Release

~~Commission~~BIOTECH ~~file~~HOLDINGS SIGNS ~~number 0-29108 _~~AN EXCLUSIVE DISTRIBUTION AND PROCUREMENT AGREEMENT FOR SUCANON TYPE II DIABETES DRUG IN LATIN AMERICA

Vancouver, B.C., July 20, 2009 - Biotech Holdings (~~Indicate~~the by"Company", ~~check~~OTC ~~mark~~BB: ~~whether~~BIOHF) reports that the ~~registrant~~Company ~~files~~through orits ~~will~~Mexican ~~file~~Subsidiary ~~annual~~Pharmaroth ~~reports~~Latin ~~under~~America S.A. ~~cover~~de C.V. has signed an agreement for distribution of ~~Form~~Sucanon, ~~20-F~~a orType ~~Form~~II ~~40-F~~diabetes drug with Merck S.A. de C.V. ("Merck") in Mexico and Latin America ("the Territory").

~~Form~~Sucanon ~~20-F Yes Form~~is ~~40-F~~currently being distributed in Mexico but the expansion into Latin America will require approvals from the various countries health authorities. NoMerck will redesign the products packaging prior to promoting the product in Mexico. Merck is expected to launch the redesigned product in October 2009.

~~(Indicate~~The byCompany ~~check~~will ~~mark~~carry ~~whether~~out ~~the~~tableting ~~registrant~~and byblister-packing ~~furnishing~~of ~~the~~Sucanon ~~information~~tablets ~~contained~~through ina ~~this~~company ~~form~~which isit ~~also~~sub-contracts ~~thereby~~in ~~furnishing~~Mexico, ~~the~~and ~~information~~sell to the ~~Commission~~blisterpacked ~~pursuant~~product to ~~Rule 12g3-2(b) under the Securities Exchange Act of 1934~~Merck.)

No Merck has been given the exclusive rights to distribute Sucanon in the Territory and is responsible for arranging and paying for all distribution, promotion, marketing and advertising expenditures.

~~Filed~~The inCompany announced earlier this ~~Form~~year ~~6-K~~that it had filed a Notice of Intention to make a proposal for its reorganization under the Bankruptcy and Insolvency Act (Canada). The Company also applied to the British Columbia Supreme Court for an order appointing Abakhan & Associates Inc. as Interim Receiver over the assets and property of the Company. The court order appointing Abakhan & Associates was granted on July 14, 2009.

~~Documents~~A ~~index~~secured creditor of the Company has been funding the operations since March 19th, 2009 and has agreed to continue to fund the Company during the proposal and reorganization under the Bankruptcy and Insolvency Act (Canada).

~~News~~For ~~Release~~background ~~dated~~information ~~March~~on 19Biotech Holdings, ~~2009~~or to receive news updates, see www.biotechltd.com.

~~SIGNATURES~~Caution regarding forward-looking statements: Biotech Holdings^ press releases may contain forward-looking statements.

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management^s best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that regulatory approval will be obtained in any specific market, nor any assurance that sales, once begun, will be material.

~~Pursuant~~George ~~to the requirements of the Securities Exchange Act of 1934~~Abakhan, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned~~CA, ~~thereunto duly authorized.~~CIRP

~~BIOTECH~~Abakhan ~~HOLDINGS~~& ~~LTD~~Associates Inc.

~~By: /s/~~As ~~Lorne~~Interim ~~Brown~~Receiver of Biotech Holdings Ltd.

Name: Lorne Brown C.F.O. and Interim C.E.O.

Date: March 19, 2009

Biotech Holdings Ltd. Makes Filing under Insolvency Legislation

Vancouver, B.C., March 19, 2009 - Biotech Holdings Ltd. ("Biotech" or the "Company", OTC BB: BIOHF; Frankfurt: 925970.F) announces that is has been unsuccessful in seeking offers for the merger, sale, refinancing or other strategic alternative for the Company. Consequently, the Company has filed a Notice of Intention to make a proposal for its reorganization under the Bankruptcy and Insolvency Act (Canada). Abakhan & Associates Inc. has consented to act as Trustee under the proposal. In light of the foregoing, the directors of the Company have indicated their intention to resign.

This release has been approved by the Board of Directors of Biotech Holdings.

Biotech Holdings Ltd. is based in Vancouver, British Columbia. Biotech Holdings shares trade on the Over the Counter Bulletin Board in the United States (OTC BB: BIOHF).

For inquiries, contact Gale Belding at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information, please visit Biotech`s website at www.biotechltd.com.

This release has been approved by the Board of Directors of Biotech Holdings.

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management`s best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.

Filing Compare · BIOTECH HOLDINGS LTD